On August 19, Novo-Nordisk A/S rose 3.02% in regular trading, trading at $47.07/share, with turnover of $211 million.

On the news front, Novo-Nordisk A/S officially initiated a clinical study named OASIS 5 on August 12, designed to evaluate the efficacy of a low-dose oral semaglutide regimen on body weight in overweight or obese patients. The study plans to enroll approximately 450 participants, with an estimated completion date of April 2028. The primary endpoint is to determine the minimum effective dose of oral semaglutide for treating overweight or obesity.

The move is viewed as a further strategic expansion by Novo-Nordisk A/S in the oral GLP-1 receptor agonist space. As the weight management market matures, the company aims to provide more precise, personalized oral treatment options by identifying the lowest dose that helps patients maintain or achieve weight loss targets. Notably, Novo-Nordisk A/S's CEO recently stated that demand for the oral version of Wegovy has exceeded expectations relative to injections, underscoring the commercial potential of this delivery format.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)